Zenas BioPharma, Inc. Overview
Pro stress-test →Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing transformative immunology-based therapies for autoimmune diseases, with its lead candidate obexelimab—a bifunctional monoclonal antibody targeting CD19 and FcγRIIb for treatment of IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company demonstrated clinical validation with obexelimab achieving a 56% reduction in risk of IgG4-RD flare in Phase 3 INDIGO trial, a pivotal development for the autoimmune space.
Strategic Profile
Pro stress-test →With pro-forma cash of approximately $403.6M and runway into Q4 2026, Zenas maintains a strong balance sheet to advance its pipeline. The company is also developing ZB002, an anti-TNFα monoclonal antibody; ZB004, a CTLA-4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody, diversifying its immunology-focused approach across multiple therapeutic mechanisms.
Competitive Landscape
Pro stress-test →Zenas operates in crowded immunology space competing against established players like Sanofi, Viridian Therapeutics, and emerging clinical-stage biotechs. The company's bifunctional antibody approach for B cell inhibition represents differentiated mechanism versus traditional monotherapy approaches, though recent setbacks in BTK inhibitor class (Sanofi's tolebrutinib failure) create broader market headwinds.
Industry Context
Zenas BioPharma, Inc. operates in Biopharmaceutical - Immunology and Autoimmune Disorders.
Key facts
Founded: 2019 · Headquarters: Waltham, Massachusetts, US · Revenue: $5.0M (2024) · Market cap: $1.85B